

PATENT ATTORNEY DOCKET NO. 47232-0009

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

	In re A	pplicati	on of: Takashi OGURA et al.)	Confirmation No.: 3181								
	Applic	ation N	o.: 10/525,974)	Group Art Unit: 1655								
	Filed:	Februa	ry 28, 2005)	Examiner: Paul C. Martin								
	For:	INTER	OD FOR TRAPPING REACTION MEDIATES BETWEEN DUCTASE AND SUBSTRATES)))									
	Commissioner for Patents U.S. Patent and Trademark Office Customer Window Mail Stop: New Application Amendment AF Issue Fee Alexandria, VA 22314												
	Sir:												
-			INFORMATION DISCL	OSURE ST	ATEMENT (IDS)								
1	Under 37 C.F.R. § 1.97(b): Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicant brings to the attention of the Examiner the documents listed on the attached PTO Form 1449. To the undersigned's knowledge, this IDS is being filed before the mailing date of a first Office Action on the merits, before the mailing date of a first Office Action on the merits after filing an RCE under § 1.114, or within three months of the application filing date.												
· •	Under 37 C.F.R. § 1.97(c): Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicant brings to the attention of the Examiner the documents listed on the attached PTO Form 1449. This IDS is being filed after the events recited in § 1.97(b) but, to the undersigned's knowledge, before the mailing date of a Final Office Action, a Notice of Allowance, or another action that closes prosecution in the application.												
			The fee of \$180.00 set forth in §	§ 1.17(p) is i	ncluded herein; or								
				m a foreign p	nation contained in this IDS was first patent office in a counterpart foreign r to the filing of this IDS.								
	Under 37 C.F.R. § 1.97(d): Pursuant to 37 C.F.R. §§ 1.56 and 1.97(d), Applicant brings to the attention of the Examiner the documents listed on the attached PTO Form 1449. This IDS is being filed after the events recited in § 1.97(c) but before payment of the issue fee.												
11/03/2006	GFREY1	00000123	The fee of \$180.00 set forth in §	§ 1.17(p) is i	ncluded herein; and								
01 FD:1808			160.00 UP										

DC\581643\1

Attorney Docket No.: 47232-0009

Page 2

Applicant submits that each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS.

A search report or other listing of documents from a counterpart, related, or other application dated <u>September 4, 2006</u> and having documents cited thereon is attached for the Examiner's consideration. Any of these documents not previously cited, and any additional documents are listed on the PTO Form 1449.

Applicant respectfully requests that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form. As for any document listed on the accompanying PTO-1449 that is in a language other than English, relevance can be understood from an enclosed English abstract or at least partial translation or from mention in the specification or in a search report for a corresponding application.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that any of the listed documents are material or constitute "prior art." If it should be determined that any of the listed documents do not constitute "prior art" under United States law, Applicant reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should any of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this Application, including fees due under 37 C.F.R. § 1.16 and 1.17 which may be required and including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0573. This paragraph is intended to be a CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R. § 1.136(a)(3).

Respectfully submitted,

DRINKER, BIDDLE & REATH LLP

Dated: October 31, 2006

CUSTOMER NO. 055694 DRINKER, BIDDLE & REATH LLP

1500 K Street, N.W., Suite 1100 Washington, D.C. 20005-1209

Tel: 202.842.8800; Fax: 202.842.8465

INFOR	MATI	ON DISCLOSURE CITATION	Attorney Docket No.: 47232-0009			Serial No.: 10/525,974			
		everal sheets if necessary)	Applicants			Page 1 of 1			
14	<u>}</u>		Takashi	OGURA et a	al.				
OCT 3 1 2006 (4) PTO Form 1449			Filing Date: February 28, 2005			Group Art Unit: 1655			
TA MADEMARK	7	U.S. PAT	TENT DOCU						
*Examiner Document						Sub			
Initial		Number	Date	Nam	Name		Class	Filing Date	
	-		-	· · · · · · · · · · · · · · · · · · ·					
	-								
	_								
	ļ								
	1		PATENT DO	CUMENTS	1	Sub	1		
		Document Number	Date	Country	Country Class			Translation YES N	
						 	 		
(Include name	of the	author (in CAPITAL LETTERS), ti	ER DOCUME	le (when appr	ropriate),	, title of the	e item (boo	k, maga:	zine,
journal, serial,	sympo	sium, catalog, etc.) date, page(s), vo	lume-issue nu	mber(s), publ	isher, cit	y and/or co	ountry when	e publis	hed.)
	CA	M.J. RYLE et al., "Nitrogenase R Evidence for Three Sequential Int	ermediates wit	th Cluster-Bo	und Carl				2000,
		vol. 39, pp 1114-1119, American	Chemical Soc	iety, Washing	gton, DC				
	CB	V. SCHÜNEMANN et al., "Interr peroxy acetic acid," FEBS Letters	nediates in the 179 (2000), r	reaction fo s p 149-154, E	ubstrate- Isevier S	free cytoch cience BV	rome P450, Amsterda	cam wit	th and
				-					
Examiner			Date Considered						
Examiner: Initial	if refe	erence considered, whether or not cit	ation is in con	formance wit	h MPEP	609; draw	line throug	h citatic	on if
not in	COIIIO	rmance and not considered. Include	copy of this id	om with next	commu	nication to	applicant.		